Clinical Trials Logo

Filter by:
NCT ID: NCT03270865 Completed - Clinical trials for DR Population- With or Without Diabetic Macular Edema

Usability and Ergonomic Evaluation of Self-Positioning System for Retinal Imaging

Start date: September 30, 2017
Phase: N/A
Study type: Interventional

The purpose of the study "Usability and Ergonomic Evaluation of Self-Positioning System for Retinal Imaging" is to enable self-operation of a monitoring device in home-simulated environment

NCT ID: NCT03270839 Recruiting - Drug Reaction Clinical Trials

Motion Sickness Medications and Vestibular Time Constant

Start date: June 1, 2017
Phase: Phase 4
Study type: Interventional

Sea sickness represents a major limitation on the performance of ships' crew. One of the challenges faced by the physician in the motion sickness clinic when prescribing anti-sea sickness medication is to select the appropriate drug for the patient. Difficulties arise due to high variability in the response to different drugs. In the case of sea sickness, the current procedure is to examine the drug's efficacy in each individual during real time exposure to sea conditions. A number of studies have documented the presence of sea sickness drug receptors in the vestibular nuclei, which determine the vestibular time constant. Two clinical vestibular tests which evaluate the time constant are the Velocity Step and OKAN tests. The purpose of the proposed study is to evaluate the influence of motion sickness drugs on the vestibular time constant, as a possible bioequivalent of drug potency in the individual subject. Eighty crew members will be recruited and divided into groups responsive and non-responsive to the sea sickness drugs scopolamine and meclizine. Subjects having a Wiker score of 7 in waves 1 meter high without drug treatment, and no improvement in symptoms after treatment will be defined as non-responsive to sea sickness drugs. Subjects having a Wiker score of 7 in waves 1 meter high without drug treatment, and a Wiker score of 4 or less after treatment, will be defined as responsive to drug therapy. Kwells, Bonine and placebo, will be assigned to each subject in a random, double-blind fashion. Each group will perform the Velocity Step and OKAN tests before, one and two hours after drug or placebo administration.

NCT ID: NCT03270397 Completed - Body Image Clinical Trials

Addressing Body Image Issues While Teaching Academic Course: The Group- Theory and Practice

Start date: August 1, 2013
Phase: N/A
Study type: Interventional

MSc. course addressing the issue of body image among nutrition students while delivering the course "The group- theory and practice". A non-randomized controlled trial was conducted between 2014 and 2016 with 135 dietetics' students in Tel Hai Academic College, Israel. Changes in body image and eating disorders features were assessed between course conclusion and baseline among participants within controlled efficacy study.

NCT ID: NCT03269695 Terminated - Ulcerative Colitis Clinical Trials

Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.

Start date: December 20, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if PF-06687234 is effective and safe as add-on therapy to infliximab in subjects with active ulcerative colitis who are not in remission.

NCT ID: NCT03269201 Enrolling by invitation - Parkinson Disease Clinical Trials

Brain Network Activation in Patients With Movement Disorders

BNA-MDi
Start date: March 1, 2019
Phase:
Study type: Observational

The diagnosis and management of movement disorders, such as Parkinson's disease (PD), parkinson-plus syndromes (PPS), dystonia, essential tremor (ET), normal pressure hydrocephalus (NPH) and others is challenging given the lack of objective diagnostic and monitoring tools with high sensitivity and specificity. A cornerstone in research of neurological disorders manifesting as MDi is the investigation of neurophysiological changes as potential biomarkers that could help in diagnosis, monitoring disease progression and response to therapies. Such a neuro-marker that would overcome the major disadvantages of clinical questionnaires and rating scales (such as the Unified Parkinson's disease rating scale -UPDRS, for PD, The Essential Tremor Rating Assessment Scale -TETRAS, for ET and others), including low test-retest repeatability and subjective judgment of different raters, would have real impact on disease diagnosis and choice of interventions and monitoring of effects of novel therapeutics, including disease modifying therapies. To address this, ElMindA has developed over the last decade a non-invasive, low-cost technology named Brain Network Activation (BNA), which is a new imaging approach that can detect changes in brain activity and functional connectivity. Results from proof-of concept studies on PD patients have demonstrated that: 1) PD patients exhibited a significant decrease in BNA scores relatively to healthy controls; 2) notable changes in functional network activity in correlation with different dopamine-agonist doses; 3) significant correlation between BNA score and the UPDRS). 4) BNA could also differentiate early PD from healthy controls

NCT ID: NCT03269175 Completed - Multiple Sclerosis Clinical Trials

BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies

Start date: September 29, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to obtain long-term clinical data from patients approximately 15 years after their first clinical event, who participated in the former BENEFIT 304747 study and were treated at least once within that study. This study will collect clinical information on the disease course, on disability, relapses, cognitive function over time, quality of life, depression, fatigue, resource use, and employment status. In addition, brain MRI is performed.

NCT ID: NCT03268954 Active, not recruiting - Clinical trials for Myelodysplastic Syndrome

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

PANTHER
Start date: November 28, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine. (An event is defined as death or transformation to AML in participants with MDS or CMML, whichever occurs first, and is defined as death in participants with low-blast AML).

NCT ID: NCT03268525 Completed - Pain, Postoperative Clinical Trials

The Effect of Local Anesthesia on Postoperative Pain in Vaginal Hysterectomy

Start date: September 1, 2017
Phase: Early Phase 1
Study type: Interventional

The investigators aim is to study the effect of pre-operative local anesthetic on post vaginal hysterectomy pain.

NCT ID: NCT03267875 Not yet recruiting - Aortic Aneurysm Clinical Trials

A Laboratory Scan of Patients With Aortic Aneurysms to IgG4 Levels in the Blood

Start date: November 8, 2017
Phase: N/A
Study type: Interventional

IgG4 Related Disease is a multi-systemic fibroenophilic disease that includes a basket of recently discovered medical conditions. The properties that bind them are: lesions similar to tumors in the mixed organs, lymphoplasms filtrate enriched with plasma IgG4 positive cells, storiform fibrosis, and often, but not always, a high level of IgG4 in the serum. This disease has been on the rise for the past two decades and since its recognition in 2001 there has been impressive progress in understanding its various manifestations, so that today almost every body system can be involved. One of the conditions associated with this disease is oritis / periortitis and aneurysms

NCT ID: NCT03266029 Completed - Clinical trials for Congestive Heart Failure

Clinical Evaluation of Cordio App in Adult ADHF Patients

Start date: May 24, 2015
Phase:
Study type: Observational

Observational study on ADHF patients at one site in Israel. After signing informed consent and undergoing screening assessments, eligible patients will record sentences into a smartphone. The app will upload the vocal data to the sponsor's servers for analysis. The patient will record at hospital: admittion, release. Before hospital release, if applicable and upon patient agrreement, an app will be installed in a smartphone in order to continue the recording at home.